TMCnet News
Heart Test Laboratories to Exhibit at the Annual AAFP ConferenceHeart Test Laboratories, Inc. announced today that the company is exhibiting at AAFP's Family Medicine Experience (FMX) Conference in Denver, Colorado Thursday, October 1 through Saturday, October 3. The Conference is attended by more than 5,000 family physicians from all over the country. Heart Test Laboratories will be exhibiting in Booth #3305 and will be presenting its innovative new product, the MyoVista. The MyoVista's breakthrough technology includes proprietary informatics that facilitate enhanced screening for heart disease by physicians. The MyoVista provides two tests in one and is easy for physicians to use. With standard 12-lead resting ECG protocols, the MyoVista provides an ECG test incorporating interpretive analysis, plus easy to understand proprietary informatics that assist a physician in identifying heart disease at an early stage. The device has a 15.6 inch high resolution touchscreen and incorporates user features and functionality commonly associated with a tablet device, which makes it intuitive and easy to use. It is ideally suited for use in both primary care and hospital environments. "Our goal is to enhance heart disease screening so that referrals to a cardiologist for diagnostic testing and preventative treatment can take place befre an adverse event occurs. We are excited to finally be at this stage of development and expect to complete our 510k submission for FDA clearance in the near future for this exciting device," said Mark Hilz, CEO Heart Test Laboratories. About Heart Test Laboratories, Inc. ("HTL") HTL develops medical devices using patented technology that focus on the early detection of heart disease. The MyoVista's innovative technology facilitates the early identification of ischemic and other heart abnormalities which can enable improved screening for coronary arterial disease and other cardiac abnormalities. The MyoVista provides two tests in one and is easy for physicians to use. By using standard 12-lead resting ECG protocols, the MyoVista provides an ECG test incorporating interpretive analysis, plus easy to understand proprietary informatics that assist a physician in identifying heart disease at an early stage. The MyoVista provides additional information to physicians in their decision process to refer patients to a cardiologist for further diagnostic testing and treatment. The MyoVista has a 15.6 inch high resolution touchscreen and incorporates user features and functionality commonly associated with a tablet device which make it intuitive and easy to use thereby reducing training time. Its proprietary informatics provide information to physicians that suggest ischemic and certain types of structural heart abnormalities. The MyoVista is ideally suited for use in both primary care and hospital environments. Heart Disease kills 7 million people worldwide each year, more than all cancers combined, and is the largest spend area in healthcare. The MyoVista helps to address the "diagnostic gap" in heart disease today, which is the identification of asymptomatic patients prior to an adverse cardiac event, such as a heart attack. HTL expects to seek FDA clearance for the MyoVista in the near future. Heart Test Laboratories is a privately held U.S. corporation which to date has been funded by private investors. For more information visit hearttestlabs.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150929005130/en/ |
